Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.

View in: PubMed

subject areas

Acute Coronary Syndrome
Aged
Angiotensin-Converting Enzyme Inhibitors
Confidence Intervals
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Hypoglycemic Agents
Male
Middle Aged
Piperidines
Prognosis
Proportional Hazards Models
Prospective Studies
Reference Values
Risk Assessment
Survival Rate
Treatment Outcome
Uracil

authors with profiles

George Bakris